共 50 条
- [22] Indefinite Valganciclovir Prophylaxis among CMV D+/R- Lung Transplant Patients Is Limited by Breakthrough CMV Infections, Toxicity and Resistance JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2011, 30 (04): : S61 - S62
- [28] Ganciclovir-Resistant (GCV-R) CMV Is Common among Lung Transplant Recipients (LTR) Receiving Alemtuzumab Induction and Valganciclovir Prophylaxis (VGC px), and Treatment with Foscarnet (FOS) Is Both Ineffective and Toxic JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2012, 31 (04): : S142 - S142
- [29] Real world effectiveness and feasibility of pharmacist-led preemptive CMV treatment in high risk (CMV D plus R-) liver transplant JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, 2023, 6 (10): : 1097 - 1102